Genmab AS

Genmab AS Change in Working Capital

The Change in Working Capital of Genmab AS (GMAB) as of Nov 22, 2026 is 225.18 M USD. In the previous year, Change in Working Capital was -1.60 B USD — a change of -114.12% (higher).

Change in Working Capital

225.18 MUSD

YoY

-114.12%

Last updated:

Change in Working Capital of Genmab AS is 2025 225.18 M USD. Change in Working Capital of Genmab AS was 2024 -1.60 B USD. It decreases by -114.12% higher compared to the previous year.

The Genmab AS Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2018
-634.37 M USD
Jan 1, 2019
-1.22 B USD
Jan 1, 2020
306.00 M USD
Jan 1, 2021
-770.00 M USD
Jan 1, 2022
-1.93 B USD
Jan 1, 2023
1.36 B USD
Jan 1, 2024
-1.60 B USD
Jan 1, 2025
225.18 M USD
The Genmab AS Change in Working Capital history
YEARChange in Working CapitalYoY
225.18 MUSD-114.12%
-1.60 BUSD-217.11%
1.36 BUSD-170.57%
-1.93 BUSD+150.65%
-770.00 MUSD-351.63%
306.00 MUSD-125.12%
-1.22 BUSD+92.00%
-634.37 MUSD-334.65%
270.35 MUSD-134.01%
-794.94 MUSD+198.66%
-266.17 MUSD-750.13%
40.94 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

Change in Working Capital of Genmab AS is 225.18 M USD in 2025.

Change in Working Capital of Genmab AS changed from -1.60 B USD to 225.18 M USD, representing a -114.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Genmab AS since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Genmab AS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genmab AS

All Key Metrics — Genmab AS